TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $500,211 | -39.6% | 55,952 | +3.8% | 0.00% | – |
| Q2 2023 | $828,104 | -32.0% | 53,913 | -0.5% | 0.00% | – |
| Q1 2023 | $1,218,441 | +55817.4% | 54,177 | -47.7% | 0.00% | -100.0% |
| Q4 2022 | $2,179 | -100.0% | 103,597 | -80.5% | 0.00% | -80.0% |
| Q3 2022 | $13,061,000 | -37.6% | 530,091 | -38.7% | 0.01% | -37.5% |
| Q2 2022 | $20,936,000 | -26.1% | 864,060 | -21.4% | 0.01% | -11.1% |
| Q1 2022 | $28,321,000 | -13.8% | 1,099,058 | +3.8% | 0.01% | -10.0% |
| Q4 2021 | $32,854,000 | +39.6% | 1,058,503 | +9.1% | 0.01% | +25.0% |
| Q3 2021 | $23,533,000 | +40.6% | 970,470 | -15.4% | 0.01% | +60.0% |
| Q2 2021 | $16,733,000 | -45.6% | 1,146,826 | -6.9% | 0.01% | -50.0% |
| Q1 2021 | $30,749,000 | -5.3% | 1,231,510 | +3.3% | 0.01% | -16.7% |
| Q4 2020 | $32,481,000 | – | 1,191,712 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |